Pfizer (NYSE:PFE) Earns Neutral Rating from Analysts at Citigroup

Citigroup began coverage on shares of Pfizer (NYSE:PFE) in a research note released on Friday, StockNewsAPI reports. The firm issued a neutral rating and a $30.00 price objective on the biopharmaceutical company’s stock.

Several other equities analysts have also weighed in on PFE. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Wednesday, October 23rd. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and increased their price target for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Barclays boosted their price objective on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, UBS Group boosted their price target on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Eight research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and an average target price of $33.58.

Pfizer Stock Down 0.7 %

Shares of NYSE PFE opened at $28.45 on Friday. Pfizer has a 1 year low of $25.20 and a 1 year high of $31.54. The firm’s 50-day moving average is $29.08 and its 200-day moving average is $28.53. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $161.21 billion, a PE ratio of -474.17, a price-to-earnings-growth ratio of 1.01 and a beta of 0.67.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same period last year, the firm earned $0.67 earnings per share. Equities analysts expect that Pfizer will post 2.67 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 5.91%. Pfizer’s dividend payout ratio is currently -2,800.00%.

Institutional Investors Weigh In On Pfizer

Hedge funds and other institutional investors have recently bought and sold shares of the company. Atlas Capital Advisors LLC increased its stake in Pfizer by 54.4% in the 1st quarter. Atlas Capital Advisors LLC now owns 1,702 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 600 shares during the last quarter. Kathmere Capital Management LLC bought a new stake in Pfizer during the first quarter worth about $203,000. Hodges Capital Management Inc. boosted its position in Pfizer by 16.9% during the first quarter. Hodges Capital Management Inc. now owns 12,127 shares of the biopharmaceutical company’s stock valued at $337,000 after purchasing an additional 1,752 shares during the last quarter. Hennion & Walsh Asset Management Inc. grew its stake in Pfizer by 16.0% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 41,275 shares of the biopharmaceutical company’s stock valued at $1,145,000 after purchasing an additional 5,682 shares in the last quarter. Finally, Griffin Asset Management Inc. increased its position in shares of Pfizer by 13.2% during the 1st quarter. Griffin Asset Management Inc. now owns 67,989 shares of the biopharmaceutical company’s stock worth $1,887,000 after purchasing an additional 7,943 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.